Others can spin it negatively - that's their prerogative.
To me it is simply great news.
As others have already pointed out the FDA focus is on "When" not "If".
Together ANP and the FDA will just review if non-clinical issues may affect the timing. So obviously it has been determined that there are no current/outstanding clinical issues preventing the final phase testing.
They are saying to ANP ... "When can you get ready for your Phase 2B/3" .. it's that simple.
GLTAH
- Forums
- ASX - By Stock
- Ann: US FDA Type C Meeting for ATL1102 in DMD
Others can spin it negatively - that's their prerogative.To me...
-
-
- There are more pages in this discussion • 54 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $88.12M |
Open | High | Low | Value | Volume |
8.5¢ | 8.6¢ | 8.3¢ | $50.76K | 597.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.6¢ | 96543 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 35000 | 0.084 |
3 | 69692 | 0.083 |
2 | 104125 | 0.082 |
3 | 287000 | 0.081 |
10 | 935186 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.086 | 96543 | 1 |
0.087 | 103691 | 1 |
0.088 | 27962 | 1 |
0.089 | 200000 | 1 |
0.090 | 604764 | 4 |
Last trade - 10.44am 13/11/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online